Richard Chen Mao
Directeur/Membre du Conseil chez Stimwave Technologies, Inc.
Profil
Richard Chen Mao currently works at Stimwave Technologies, Inc., as Director.
Postes actifs de Richard Chen Mao
| Sociétés | Poste | Début |
|---|---|---|
Stimwave Technologies, Inc.
 Stimwave Technologies, Inc. BiotechnologyHealth Technology Part of Curonix LLC, Stimwave Technologies, Inc. is a privately held medical device company based in Pompano Beach, FL. Stimwave specializes in the development, manufacture, and commercialization of wirelessly powered, injectable, microtechnology neurostimulators. These miniature neurostimulators offer patients a convenient, safe, minimally invasive, and cost-effective solution for pain management. The company's goal is to become the leading provider of neuromodulation technology, making it more accessible to patients globally and reducing the economic burden of pain management. Stimwave's FDA-cleared product portfolio includes peripheral nerve stimulation (PNS) and spinal cord stimulation (SCS) products that provide a drug-free alternative for treating chronic pain by blocking pain signals to the brain. The CEO of the company is Aure Bruneau. Stimwave operates worldwide through its operating subsidiaries and was acquired by Curonix LLC on November 01, 2022. | Directeur/Membre du Conseil | - |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 1 |
|---|---|
Stimwave Technologies, Inc.
Stimwave Technologies, Inc. BiotechnologyHealth Technology Part of Curonix LLC, Stimwave Technologies, Inc. is a privately held medical device company based in Pompano Beach, FL. Stimwave specializes in the development, manufacture, and commercialization of wirelessly powered, injectable, microtechnology neurostimulators. These miniature neurostimulators offer patients a convenient, safe, minimally invasive, and cost-effective solution for pain management. The company's goal is to become the leading provider of neuromodulation technology, making it more accessible to patients globally and reducing the economic burden of pain management. Stimwave's FDA-cleared product portfolio includes peripheral nerve stimulation (PNS) and spinal cord stimulation (SCS) products that provide a drug-free alternative for treating chronic pain by blocking pain signals to the brain. The CEO of the company is Aure Bruneau. Stimwave operates worldwide through its operating subsidiaries and was acquired by Curonix LLC on November 01, 2022. | Health Technology |